These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29038234)

  • 21. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.
    Dromain C; Loaiza-Bonilla A; Mirakhur B; Beveridge TJR; Fojo AT
    Oncologist; 2021 Apr; 26(4):e632-e638. PubMed ID: 33393112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
    Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
    Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
    Mirakhur B; Pavel ME; Pommier RF; Fisher GA; Phan AT; Massien C; Liyanage N; Lowenthal SP; Vinik AI
    Endocr Pract; 2018 Aug; ():. PubMed ID: 30084687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
    Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
    Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
    Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
    Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].
    Bencsiková B
    Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
    Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
    Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.
    Bisschops R; De Ruyter V; Demolin G; Baert D; Moreels T; Pattyn P; Verhelst H; Lepoutre L; Arts J; Caenepeel P; Ooghe P; Codden T; Maisonobe P; Petrens E; Tack J
    Clin Ther; 2016 Aug; 38(8):1902-1911.e2. PubMed ID: 27423779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
    Kang J; Yoo C; Hwang HS; Hong SM; Kim KP; Kim SY; Hong YS; Kim TW; Ryoo BY
    Invest New Drugs; 2019 Aug; 37(4):763-770. PubMed ID: 30536151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A; Munir M; Syed O; Mehta V; Kaur R; Kumar A; Sridhar A; Sood A; Gupta R
    Expert Opin Drug Saf; 2024 Aug; 23(8):949-957. PubMed ID: 38847075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
    Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
    Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
    Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
    Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.